Vanda Pharmaceuticals Inc Revenue Growth Rates (VNDA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vanda Pharmaceuticals Inc   (NASDAQ: VNDA)
 

VNDA's Revenue Growth by Quarter and Year

Vanda Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VNDA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 50.53
1st Quarter March 51.72
FY 102.25

VNDAs Annual Revenue
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 216.11 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 198.77 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 192.64 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 254.38 millions
Vanda Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 268.68 millions




VNDA Revenue second quarter 2026 Y/Y Growth Comment
Vanda Pharmaceuticals Inc reported decrease in Revenue in the second quarter 2026 by -3.92% to $ 50.53 millions, from the same quarter in 2025.
The decrease in the second quarter 2026 Vanda Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 17.95%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Vanda Pharmaceuticals Inc ' s Revenue decline of -3.92% ranks overall at the positon no. 2514 in the second quarter 2026.


VNDA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 7.58 % 17.5 % -29.79 %
3rd Quarter September - 18.07 % 22.75 % -40.57 %
2nd Quarter June -3.92 % 4.2 % 9.57 % -28.47 %
1st Quarter March 3.36 % 5.44 % -24.06 % 3.84 %
FY   - 8.72 % 3.18 % -

Financial Statements
Vanda Pharmaceuticals Inc 's second quarter 2026 Revenue $ 50.53 millions VNDA's Income Statement
Vanda Pharmaceuticals Inc 's second quarter 2025 Revenue $ 52.59 millions Quarterly VNDA's Income Statement


VNDA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.71 % 11.63 % 16.62 %
3rd Quarter September - 6.98 % -5.59 % -15.72 %
2nd Quarter June -2.3 % 5.1 % 6.34 % -26.3 %
1st Quarter March -9.61 % -5.92 % 4.84 % -3.07 %
FY (Year on Year)   - 8.72 % 3.18 % -


Back to VNDA Growth rate Comparisons >> Back to VNDA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2514

Revenue Y/Y Growth Statistics
High Average Low
119.16 % 17.95 % -30.81 %
(Dec 31 2015)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2514
Revenue Y/Y Growth Statistics
High Average Low
119.16 % 17.95 % -30.81 %
(Dec 31 2015)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vanda Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
44.11 % 3.45 % -26.31 %
(Mar 31 2015)  


VNDA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Vanda Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -2.3% to $ 50.53 millions, from $ 51.72 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 95 other companies have achieved higher Revenue quarter on quarter growth. While Vanda Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2157.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #274
Overall #2157
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #96
Healthcare Sector #274
Overall #2157
Revenue Q/Q Growth Statistics
High Average Low
44.11 % 3.45 % -26.31 %
(Mar 31 2015)  


VNDA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Vanda Pharmaceuticals Inc disclosed fall in Revenue from the first quarter by -2.3% to $ 50.53 millions, from $ 51.72 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 95 other companies have achieved higher Revenue quarter on quarter growth. While Vanda Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2157.


Vanda Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 215.72 $ 217.78 $ 216.11 $ 212.07 $ 203.47
Y / Y Revenue Growth (TTM) 6.02 % 8.16 % 8.72 % 11.12 % 11.78 %
Year on Year Revenue Growth Overall Ranking # 1316 # 964 # 453 # 2597 # 2644
Seqeuential Revenue Change (TTM) -0.95 % 0.78 % 1.9 % 4.23 % 1.05 %
Seq. Revenue Growth (TTM) Overall Ranking # 2514 # 2309 # 1534 # 1567 # 1829


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Vanda Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 216 millions, company would post below average annual Revenue growth of 1.05% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Vanda Pharmaceuticals Inc 's Revenue growth from the 51.72% growth in Mar 31 2026.

In the Healthcare sector 227 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 964 to 1316.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 228
Overall # 1316

Revenue TTM Y/Y Growth Statistics
High Average Low
119.16 %
 17.95 %
-30.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2514
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Vanda Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 216 millions, company would post below average annual Revenue growth of -30.81% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Vanda Pharmaceuticals Inc 's Revenue growth from the 51.72% growth in Mar 31 2026.

In the Healthcare sector 227 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 964 to 1316.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 228
Overall # 1316

Revenue TTM Y/Y Growth Statistics
High Average Low
119.16 %
17.95 %
-30.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2514




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VNDA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bio rad Laboratories Inc -0.05%$ -0.046 millions
Seer Inc -0.29%$ -0.289 millions
Dyadic International Inc -0.57%$ -0.568 millions
Teva Pharmaceutical Industries Limited-0.81%$ -0.814 millions
Aytu Biopharma Inc-0.91%$ -0.911 millions
Neuropace Inc -1.32%$ -1.323 millions
Ardent Health Inc -1.40%$ -1.400 millions
Sunshine Biopharma Inc -1.56%$ -1.557 millions
Pacific Biosciences Of California Inc -1.71%$ -1.706 millions
United Therapeutics Corporation-1.92%$ -1.916 millions
Orasure Technologies Inc-1.93%$ -1.930 millions
Pulmonx Corporation-1.93%$ -1.931 millions
Volitionrx Limited-1.97%$ -1.975 millions
Organon and Co -2.26%$ -2.258 millions
Airsculpt Technologies Inc -2.53%$ -2.527 millions
Charles River Laboratories International inc -2.72%$ -2.718 millions
Perrigo Company Plc-3.17%$ -3.171 millions
Zai Lab Limited-3.33%$ -3.333 millions
Vanda Pharmaceuticals Inc -3.92%$ -3.919 millions
Teladoc Health Inc -3.95%$ -3.952 millions
Dentsply Sirona Inc -4.06%$ -4.060 millions
Sanuwave Health Inc -4.18%$ -4.181 millions
Treace Medical Concepts Inc -4.24%$ -4.244 millions
Fortrea Holdings Inc -4.52%$ -4.519 millions
Positron Corporation-6.91%$ -6.907 millions
Standard Biotools Inc -7.05%$ -7.046 millions
Inspire Medical Systems inc -7.32%$ -7.316 millions
Adapthealth Corp -7.50%$ -7.505 millions
China Pharma Holdings Inc-7.55%$ -7.548 millions
Skinhealth Systems Inc -7.68%$ -7.680 millions


About Vanda Pharmaceuticals Inc Revenue Growth Rates (VNDA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vanda Pharmaceuticals Inc (CIK 1347178).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-053855
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vanda Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.